AI assistant
Compugen Ltd. Regulatory Filings 2021
6734_rns_2021-09-14_6f79db45-8f08-4111-b5b4-77697641b336.pdf
Regulatory Filings
Open in viewerOpens in your device viewer
FOR IMMEDIATE RELEASE
Compugen to Present at the Cantor Global Healthcare Conference
HOLON, ISRAEL, September 14, 2021 –– Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Cantor Global Healthcare Conference on Thursday, September 30, 2021 at 1:20 pm ET.
A live webcast of the presentation will be available on the Investor Relations section of Compugen's website at www.cgen.com. A replay will be available following the event.
About Compugen
Compugen is a clinical-stage discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen's lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing Phase 1 studies as a single agent and in dual, and triple combination. COM902, Compugen's second fully owned clinical antibody targeting TIGIT, for the treatment of solid and hematological tumors, is undergoing Phase 1 studies as a single agent and in dual combination. Compugen's therapeutic pipeline also includes early-stage immuno-oncology programs focused largely on myeloid targets. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For additional information, please visit Compugen's corporate website at www.cgen.com.
Company contact:
Yvonne Naughton, PhD Head of Investor Relations and Corporate Communications Email: [email protected] Tel: +1 (628) 241-0071
Investor Relations contact: John Mullaly LifeSci Advisors, LLC Email: [email protected] Tel: +1 (617) 429-3548